BRISBANE, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced that it has received additional proceeds of approximately $5.5 million from existing investors through an amendment to its term loan facility. Aside from the increase in the amount extended, the term loan facility remains unchanged.

The amendment brings the total principal amount of the loan from the lenders to $9.2 million. The proceeds will provide additional working capital to the company and support the ongoing development of benznidazole for potential U.S. approval to treat Chagas disease, a neglected tropical disease, and lenzilumab for chronic myelomonocytic leukemia (CMML), a rare pediatric disease, as well as current partnering efforts with ifabotuzumab.

"We appreciate the continued support of our key investors as we remain on track in our development of benznidazole and lenzilumab," said Cameron Durrant, MD, KaloBios chairman and CEO. "We will continue to execute on our strategic priorities to generate value for all of our stakeholders."

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially juvenile myelomonocytic leukemia, or JMML. For more information, visit

If you liked this article you might like

KaloBios Pharmaceuticals, Potash and Radian: Doug Kass' Views

Stocks Slip on 2016 Outlook of Middling Economic Growth

Energy Lags Wall Street as Crude Oil Spirals Lower

KaloBios Looks to Restructure While Under Court Protection in Delaware

KaloBios Pharmaceuticals (KBIO) Files For Bankruptcy, Stock Delisted From Nasdaq